Related Experiment Videos
Abnormal 5-HT1D receptor function in major depression: a neuropharmacological challenge study using sumatriptan
A J Cleare1, R M Murray, R A Sherwood
1Department of Psychological Medicine, King's College School of Medicine and Dentistry, London.
Psychological Medicine
|May 8, 1998
Summary
Major depression may involve reduced sensitivity in serotonin 5-HT1D receptors. Sumatriptan
Area of Science:
- Neuroscience
- Endocrinology
- Psychiatry
Background:
- Sumatriptan acts as a specific agonist at serotonin 5-HT1D receptors.
- This receptor interaction stimulates growth hormone (GH) release and inhibits prolactin (PRL) release.
Purpose of the Study:
- To investigate the function of 5-HT1D receptors in patients with major depression.
- To compare the effects of sumatriptan on GH and PRL release in depressed patients versus healthy controls.
Main Methods:
- 11 patients with unipolar major depression and 11 matched controls received a 6 mg subcutaneous injection of sumatriptan.
- Serum GH and PRL levels were measured at multiple time points post-injection (0, 15, 30, 45, 60, and 90 minutes).
Main Results:
- A significantly blunted maximal rise in GH was observed in depressed patients (60% showed no increase) compared to controls (18% showed no increase).
- No significant differences in prolactin (PRL) responses were found between the depressed group and the control group.
Conclusions:
- The findings suggest a reduced sensitivity of 5-HT1D receptors in individuals with major depression.
- Combined with existing research on 5-HT1A receptors, these results imply that both 5-HT1A and 5-HT1D autoreceptors may exhibit reduced function in major depression.